Correction to: miR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas

Following publication of the original article [1], the authors reported that they had supplied the incorrect figure for publication.

Cao et al. BMC Cancer (2018) 18:1293.

https://doi.org/10.1186/s12885-018-5205-9

Following publication of the original article [1], the authors reported that they had supplied the incorrect figure for publication. The correct figure is displayed below. The authors apologise for the error.

Fig. 2.

miR-18a promotes cell proliferation in EBV-positive lymphoma cells. a miR-18a promoted tumor cell growth in vitro in EBV-positive lymphoma cell lines. CCK-8 cell viability assay was performed after the transfection of miR-18a mimics or miR-18a inhibitor into EBV-positive lymphoma cell lines (P3HR-1, Raji, EBV infected BJAB) and the EBV-negative lymphoma cell line BJAB. The data represented the mean values of five repeats. The data are shown as the means±SD (Student T-test, *p < 0.05). b Flow cytometry analysis of the cell cycle after the transfection of miR-18a. c Cell cycle distribution of cells in S phase. The data were presented as the means±SD of four replicates (Student T-test, *p < 0.05; **p < 0.01)